ADC Therapeutics (ADCT) EPS (Basic) Growth (1y) (2021 - 2026)
ADC Therapeutics (ADCT) EPS (Basic) Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.88 Bn | 132.03 Bn | 2.84 Bn | 7.74% |
| 2 | Regeneron Pharmaceuticals | 86.62 Bn | 78.62 Bn | 3.93 Bn | -4.72% |
| 3 | Argenx Se | 65.28 Bn | 60.10 Bn | 1.37 Bn | 88.81% |
| 4 | Moderna | 61.39 Bn | 56.25 Bn | 52.00 Mn | 7.59% |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 143.95% |
| 6 | Alnylam Pharmaceuticals | 31.37 Bn | 28.06 Bn | 992.69 Mn | 322.67% |
| 7 | BioNTech SE | 28.76 Bn | 10.37 Bn | 668.28 Mn | -147.33% |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 96.41% |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | -16.29% |
| 10 | ADC Therapeutics | 152.44 Mn | -66.66 Mn | 17.14 Mn | 78.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 78.54% |
| Mar 31, 2026 | 40.60% |
| Sep 30, 2025 | 28.00% |
| Jun 30, 2025 | -32.57% |
| Mar 31, 2025 | 35.38% |
| Sep 30, 2024 | 24.29% |
| Jun 30, 2024 | 36.50% |
| Mar 31, 2024 | 24.23% |
| Sep 30, 2023 | 14.71% |
| Jun 30, 2023 | 29.32% |
| Mar 31, 2023 | -239.09% |
| Dec 31, 2022 | 49.82% |
| Sep 30, 2022 | 30.74% |
| Jun 30, 2022 | 11.50% |
| Mar 31, 2022 | 67.71% |
| Dec 31, 2021 | 46.19% |
| Sep 30, 2021 | -225.25% |
| Jun 30, 2021 | 53.02% |
| Mar 31, 2021 | 21.28% |